Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell-gp100-MART-1 antigen vaccine
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Subcutaneous, Intravenous, Intranodal
01
Overview
An autologous dendritic cell-based cancer vaccine in which a patient's own dendritic cells are harvested and pulsed or transduced with melanoma-associated antigens gp100 and MART-1 (Melan-A). The modified dendritic cells present these antigens to the immune system, aiming to stimulate both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells specific for the tumor antigens. This approach is designed to induce an adaptive immune response against melanoma cells expressing gp100 and MART-1. The primary indication is metastatic melanoma. Clinical studies have shown that this therapy can activate both helper and killer T-cell responses in vivo[2][5]. The mechanism of action involves enhanced antigen presentation by mature autologous dendritic cells leading to targeted anti-tumor immunity[2][3][5].
- Other names
- gp100/MART-1–transduced dendritic cell vaccineAdV-MART1-transduced DC vaccineAdV-MART-1-transduced DC vaccineAdV-MART 1-transduced DC vaccineautologous dendritic cell melanoma antigen vaccine
Beyond the preview
Go deeper on dendritic cell-gp100-MART-1 antigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell-gp100-MART-1 antigen vaccine.